Clinical trial NCT01762644 - References

Type 1 Diabetes — The Insulin Independence Trial (IIT) Evaluating the Safety and Efficacy of Oral Cyclosporine and Oral Omeprazole for Insulin Independence Among Recent Onset Type 1 Diabetes Patients

Citation(s)

•   Assan R, Blanchet F, Feutren G, Timsit J, Larger E, Boitard C, Amiel C, Bach JF
  Normal renal function 8 to 13 years after cyclosporin A therapy in 285 diabetic patients. Diabetes Metab Res Rev. 2002 Nov-Dec;18(6):464-72.
•   Bougneres PF, Carel JC, Castano L, Boitard C, Gardin JP, Landais P, Hors J, Mihatsch MJ, Paillard M, Chaussain JL, et al
  Factors associated with early remission of type I diabetes in children treated with cyclosporine. N Engl J Med. 1988 Mar 17;318(11):663-70.
•   Cyclosporin-induced remission of IDDM after early intervention
  Association of 1 yr of cyclosporin treatment with enhanced insulin secretion. The Canadian-European Randomized Control Trial Group. Diabetes. 1988 Nov;37(11):1574-82.
•   Eisenbarth GS Immunotherapy of diabetes and selected autoimmune diseases, CRC Press, Inc
  1989:61-72.
•   Feutren G, Papoz L, Assan R, Vialettes B, Karsenty G, Vexiau P, Du Rostu H, Rodier M, Sirmai J, Lallemand A, et al
  Cyclosporin increases the rate and length of remissions in insulin-dependent diabetes of recent onset. Results of a multicentre double-blind trial. Lancet. 1986 Jul 19;2(8499):119-24.
•   Griffin KJ, Thompson PA, Gottschalk M, Kyllo JH, Rabinovitch A
  Combination therapy with sitagliptin and lansoprazole in patients with recent-onset type 1 diabetes (REPAIR-T1D): 12-month results of a multicentre, randomised, placebo-controlled, phase 2 trial. Lancet Diabetes Endocrinol. 2014 Sep;2(9):710-8. doi: 10.1016/S2213-8587(14)70115-9. Epub 2014 Jul 2.
•   Jang JY, Kim SW, Han JK, Park SJ, Park YC, Joon Ahn Y, Park YH
  Randomized prospective trial of the effect of induced hypergastrinemia on the prevention of pancreatic atrophy after pancreatoduodenectomy in humans. Ann Surg. 2003 Apr;237(4):522-9.
•   Levetan C, Pozzilli P, Jovanovic L, Schatz D
  Proposal for generating new beta cells in a muted immune environment for type 1 diabetes. Diabetes Metab Res Rev. 2013 Nov;29(8):604-6. doi: 10.1002/dmrr.2435.
•   Meier JJ, Ritzel RA, Maedler K, Gurlo T, Butler PC
  Increased vulnerability of newly forming beta cells to cytokine-induced cell death. Diabetologia. 2006 Jan;49(1):83-9. Epub 2005 Dec 2.
•   Rigby MR
  Non-immune-based treatment for type 1 diabetes: the way to go? Lancet Diabetes Endocrinol. 2014 Sep;2(9):681-2. doi: 10.1016/S2213-8587(14)70139-1. Epub 2014 Jul 2.
•   Singh PK, Hota D, Dutta P, Sachdeva N, Chakrabarti A, Srinivasan A, Singh I, Bhansali A
  Pantoprazole improves glycemic control in type 2 diabetes: a randomized, double-blind, placebo-controlled trial. J Clin Endocrinol Metab. 2012 Nov;97(11):E2105-8. doi: 10.1210/jc.2012-1720. Epub 2012 Aug 17.
•   Skyler JS, Rabinovitch A
  Cyclosporine in recent onset type I diabetes mellitus. Effects on islet beta cell function. Miami Cyclosporine Diabetes Study Group. J Diabetes Complications. 1992 Apr-Jun;6(2):77-88.
•   Sobel DO, Henzke A, Abbassi V
  Cyclosporin and methotrexate therapy induces remission in type 1 diabetes mellitus. Acta Diabetol. 2010 Sep;47(3):243-50. doi: 10.1007/s00592-010-0188-2. Epub 2010 May 4.

A Phase IIB/III Multicenter Randomized Trial to Evaluate the Combination of Low-Dose Cyclosporine and Omeprazole Versus Omeprazole Alone in Participants With New Onset Type 1 Diabetes.

Details for clinical trial NCT01762644